3-(3-Fluorophenyl)-3-hydroxybutan-2-one | 936231-75-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3-Fluorophenyl)-3-hydroxybutan-2-one
• CAS: 936231-75-3
• 化学式: C₁₀H₁₁FO₂
• 分子量: 182.195
• InChiKey: MFYIQHCMFMFPIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(3-Fluorophenyl)-3-hydroxybutan-2-one 在 lithium hydroxide 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 5-(3-fluoro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid
  参考文献：
  名称：

  Analogues of Acifran:  Agonists of the High and Low Affinity Niacin Receptors, GPR109a and GPR109b

  摘要：

  Recently identified GPCRs, GPR109a and GPR109b, the high and low affinity receptors for niacin, may represent good targets for the development of HDL elevating drugs for the treatment of atherosclerosis. Acifran, an agonist of both receptors, has been tested in human subjects, yet until recently very few analogs had been reported. We describe a series of acifran analogs prepared using newly developed synthetic pathways and evaluated as agonists for GPR109a and GPR109b, resulting in identification of compounds with improved activity at these receptors.

  DOI：

  10.1021/jm070022x
• 作为产物：
  描述：

  3'-氟苯乙酮 在 甲醇 、 正丁基锂 、 mercury(II) perchlorate 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 生成 3-(3-Fluorophenyl)-3-hydroxybutan-2-one
  参考文献：
  名称：

  Analogues of Acifran:  Agonists of the High and Low Affinity Niacin Receptors, GPR109a and GPR109b

  摘要：

  Recently identified GPCRs, GPR109a and GPR109b, the high and low affinity receptors for niacin, may represent good targets for the development of HDL elevating drugs for the treatment of atherosclerosis. Acifran, an agonist of both receptors, has been tested in human subjects, yet until recently very few analogs had been reported. We describe a series of acifran analogs prepared using newly developed synthetic pathways and evaluated as agonists for GPR109a and GPR109b, resulting in identification of compounds with improved activity at these receptors.

  DOI：

  10.1021/jm070022x

文献信息

• ELECTRO-OPTIC POLYMER
  申请人：NATIONAL INSTITUTE OF INFORMATION AND COMMUNICATIONS TECHNOLOGY

  公开号：US20210032228A1

  公开（公告）日：2021-02-04

  The present invention provides an electro-optic polymer (EO polymer) comprising an electro-optic molecule (EO molecule) and a base polymer. The EO polymer of the present invention has good performance over the entire optical communication wavelength range and therefore can preferably be used for the production of optical modulators, optical switches, optical transceivers, optical phased arrays, LiDAR (light detection and ranging) devices, electric field sensors, terahertz wave generators and detectors, etc.

  本发明提供了一种电光聚合物（EO聚合物），包括电光分子（EO分子）和基础聚合物。本发明的EO聚合物在整个光通信波长范围内具有良好的性能，因此可以优选用于光调制器、光开关、光收发器、光子阵列、激光雷达（LiDAR）、电场传感器、太赫兹波发生器和探测器等的生产。
• [EN] ELECTRO-OPTICAL POLYMER<br/>[FR] POLYMÈRE ÉLECTRO-OPTIQUE<br/>[JA] 電気光学ポリマー
  申请人：NAT INST INF & COMM TECH

  公开号：WO2019151318A1

  公开（公告）日：2019-08-08

  π電子供与体とπ電子受容体がπ共役ブリッジを介して共役した電気光学分子とベースポリマーを含み、光通信波長帯全域（波長１２６０ｎｍ～１６２５ｎｍ）での、電気光学係数（ＥＯ係数）が３０ｐｍ／Ｖ以上であり、かつ、下記数式で定義される性能指数（Ｆｉｇｕｒｅ　ｏｆ　Ｍｅｒｉｔ：ＦＯＭ）が１０×１０－６ｃｍ／ｄＢＶ以上である、電気光学ポリマー。本発明の電気光学ポリマーは、光通信波長帯全域における性能に優れることから、光変調器、光スイッチ、光トランシーバー、光フェーズドアレイ、ＬｉＤＡＲ（Light and Detection and Ranging）、電界センサー、又はテラヘルツ発生・検出装置等に好適に用いることができる。〔式中、ｎ：屈折率、ｒ：EO係数、ａ ｍａｘ：使用波長帯での吸収係数の最大値、λ：波長〕
• Analogues of Acifran:  Agonists of the High and Low Affinity Niacin Receptors, GPR109a and GPR109b
  作者：Jae-Kyu Jung、Benjamin R. Johnson、Tracy Duong、Marc Decaire、Jane Uy、Tawfik Gharbaoui、P. Douglas Boatman、Carleton R. Sage、Ruoping Chen、Jeremy G. Richman、Daniel T. Connolly、Graeme Semple

  DOI：10.1021/jm070022x

  日期：2007.4.1

  Recently identified GPCRs, GPR109a and GPR109b, the high and low affinity receptors for niacin, may represent good targets for the development of HDL elevating drugs for the treatment of atherosclerosis. Acifran, an agonist of both receptors, has been tested in human subjects, yet until recently very few analogs had been reported. We describe a series of acifran analogs prepared using newly developed synthetic pathways and evaluated as agonists for GPR109a and GPR109b, resulting in identification of compounds with improved activity at these receptors.